- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.08. | Camp4 Therapeutics GAAP EPS of -$0.58 misses by $0.37 | 1 | Seeking Alpha | ||
| 13.08. | Camp4 Therapeutics Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| CAMP4 THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.08. | Camp4 Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 04.08. | CAMP4 closes $50.1 million second tranche of private placement | 1 | Investing.com | ||
| 04.08. | Camp4 Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 04.08. | CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement | 153 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory... ► Artikel lesen | |
| 27.07. | CAMP4 receives Australian clearance for SYNGAP1 therapy trial | 3 | Investing.com | ||
| 27.07. | CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder | 349 | GlobeNewswire (Europe) | Planned first-in-human clinical trial to assess a disease modifying intervention for patients with SYNGAP1-related disorder Regulatory milestone enables Company to raise up to $50 million through... ► Artikel lesen | |
| 27.07. | Camp4 Therapeutics Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 17.07. | CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 19.06. | CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 16.06. | Potenzial von CMP-002: JPMorgan stuft CAMP4 Therapeutics auf "Overweight" hoch | 10 | Investing.com Deutsch | ||
| 16.06. | JPMorgan upgrades CAMP4 Therapeutics stock rating on CMP-002 potential | 2 | Investing.com | ||
| 12.06. | Camp4 Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 10.06. | Chardan initiates CAMP4 Therapeutics stock with buy rating | 2 | Investing.com | ||
| 21.05. | CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 14.05. | Camp4 Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | CAMP4 reports positive preclinical seizure data for CMP-002 | 1 | Investing.com | ||
| 14.05. | CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder | 1 | GlobeNewswire (USA) | ||
| 08.05. | Camp4 Therapeutics GAAP EPS of -$0.32 misses by $0.11 | 2 | Seeking Alpha |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CLINUVEL | 5,318 | -0,26 % | Clinuvel Pharmaceuticals Ltd - 6-K, Report of foreign issuer | ||
| EDITAS MEDICINE | 2,750 | +0,73 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,680 | +1,20 % | B.Riley stuft Cardiol Therapeutics mit Kauf ein: Kursziel impliziert über 400 % Potenzial | ||
| CELLECTAR BIOSCIENCES | 2,520 | -0,40 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates | Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program Presented Data from... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 0,840 | +4,02 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update | Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated... ► Artikel lesen | |
| CYTODYN | 0,192 | 0,00 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease | Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 4,958 | -2,88 % | Emergent BioSolutions Reports Second Quarter 2026 Financial Results | Second Quarter 2026 Total Revenues of $234.3 million, an improvement of 66% versus prior yearSecond Quarter 2026 Net Loss of $180.2 million worsening 1,402% versus prior year, largely due to a $191.3... ► Artikel lesen | |
| DENALI THERAPEUTICS | 20,870 | +0,72 % | Denali Therapeutics Inc.: Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million | Proceeds from transaction to support advancement of Denali's broad TransportVehicle-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseasesDenali was awarded Priority... ► Artikel lesen | |
| CEL-SCI | 1,310 | +1,55 % | CEL-SCI Corporation: Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients | Peer-reviewed publication highlights Multikine's overall survival benefit in low PD-L1 oral cancer patients and expands scientific awareness as CEL-SCI is preparing to enroll patients in Confirmatory... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,215 | 0,00 % | Coherus Oncology, Inc. - 8-K, Current Report | ||
| CURIS | 1,462 | +14,43 % | Curis, Inc. Announces Pricing of $5.6 Million Public Offering | LEXINGTON, Mass., Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally... ► Artikel lesen | |
| FATE THERAPEUTICS | 2,074 | 0,00 % | Fate Therapeutics, Inc.: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis | First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites Trial advances FT819 toward a potential accelerated... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,875 | +3,27 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan ("Varseta-M") for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) | - Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in... ► Artikel lesen | |
| FAETH THERAPEUTICS | 28,400 | -1,39 % | XFRA 4070: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| CYBIN | 10,580 | +1,54 % | Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board | Former Intra-Cellular Therapies, Inc. ("Intra-Cellular") executives bring complementary experience in organizational scale-up, central nervous system ("CNS") drug development, regulatory approvals... ► Artikel lesen |
Das Unternehmen CAMP4 THERAPEUTICS CORP kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,010 (+0,24 %) liegt der Kurs bei 4,160 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CAMP4 THERAPEUTICS CORP finden Sie auf Wallstreet Online.